↓ Skip to main content

Cochrane Database of Systematic Reviews

Immunotherapy for diabetic amyotrophy

Overview of attention for article published in Cochrane database of systematic reviews, July 2017
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (59th percentile)

Mentioned by

5 tweeters


23 Dimensions

Readers on

138 Mendeley
Immunotherapy for diabetic amyotrophy
Published in
Cochrane database of systematic reviews, July 2017
DOI 10.1002/14651858.cd006521.pub4
Pubmed ID

Yee Cheun Chan, Yew Long Lo, Edwin SY Chan


People with diabetes mellitus (DM) sometimes present with acute or subacute, progressive, asymmetrical pain and weakness of the proximal lower limb muscles. The various names for the condition include diabetic amyotrophy, diabetic lumbosacral radiculoplexus neuropathies, diabetic femoral neuropathy or Bruns-Garland syndrome. Some studies suggest that diabetic amyotrophy may be an immune-mediated inflammatory microvasculitis causing ischaemic damage of the nerves. Immunotherapies would therefore be expected to be beneficial. This is the second update of a review first published in 2009. To review the evidence from randomised trials for the efficacy of any form of immunotherapy in the treatment of diabetic amyotrophy. On 5 September 2016 we searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE and Embase. We also contacted authors of relevant publications and other experts to obtain additional references, unpublished trials, and ongoing trials. We intended to include all randomised and quasi-randomised trials of any immunotherapy in participants with the condition fulfilling all the following: diabetes mellitus as defined by internationally recognised criteria; acute or subacute onset of pain and lower motor neuron weakness involving predominantly the proximal muscles of the lower limbs; weakness that is not confined to one nerve or nerve root distribution; and exclusion of other causes of lumbosacral radiculopathies and plexopathy. Two authors independently examined all references retrieved by the search to select those meeting the inclusion criteria. We found only one completed placebo-controlled trial (N = 75) using intravenous methylprednisolone in diabetic amyotrophy (Dyck 2006). The results have not been fully published and were not available for analysis. The risk of bias was unclear because there was too little information to make a judgement, but we considered the trial at high risk of selective reporting. The published abstract did not report adverse events. We found no additional trials when the searches were updated in September 2016. There is presently no evidence from randomised trials to support a positive or negative effect of any immunotherapy in the treatment in diabetic amyotrophy.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 138 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 <1%
Unknown 137 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 24 17%
Student > Bachelor 15 11%
Researcher 14 10%
Student > Postgraduate 11 8%
Other 10 7%
Other 32 23%
Unknown 32 23%
Readers by discipline Count As %
Medicine and Dentistry 53 38%
Nursing and Health Professions 11 8%
Neuroscience 7 5%
Agricultural and Biological Sciences 6 4%
Biochemistry, Genetics and Molecular Biology 4 3%
Other 23 17%
Unknown 34 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 August 2017.
All research outputs
of 16,578,367 outputs
Outputs from Cochrane database of systematic reviews
of 11,536 outputs
Outputs of similar age
of 273,733 outputs
Outputs of similar age from Cochrane database of systematic reviews
of 254 outputs
Altmetric has tracked 16,578,367 research outputs across all sources so far. This one is in the 47th percentile – i.e., 47% of other outputs scored the same or lower than it.
So far Altmetric has tracked 11,536 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.4. This one is in the 24th percentile – i.e., 24% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 273,733 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.
We're also able to compare this research output to 254 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.